CUPERTINO, Calif., March 23, 2022 /PRNewswire/ — DURECT Company (Nasdaq: DRRX) nowadays declared that Dr. James E. Brown, President and CEO, will be collaborating in a panel discussion at the Cantor Virtual Unusual Orphan Sickness Summit hosted by Kristen Kluska, Taking care of Director, Biotechnology Investigation Analyst of Cantor Fitzgerald. The title of the panel is “Little but Mighty: Revolutionary Strategies in Tackling Some of the Greater Uncommon Orphan Condition Markets” and will choose put at 1:00 pm ET on Wednesday, March 30, 2022.
If you have interest in participating in the Cantor Virtual Uncommon Orphan Ailment Summit, make sure you achieve out to your Cantor Fitzgerald consultant.
About DURECT Company
DURECT is a biopharmaceutical business fully commited to transforming the cure of acute organ harm and persistent liver ailments by advancing novel and probably lifesaving therapies based on its endogenous epigenetic regulator method. Larsucosterol (also regarded as DUR-928), DURECT’s lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and affiliated with hypermethylation located in liquor-connected hepatitis (AH) people. Larsucosterol is in scientific advancement for the opportunity procedure of AH, for which Fda has granted a Fast Observe Designation non-alcoholic steatohepatitis (NASH) is also remaining explored. In addition, POSIMIR® (bupivacaine remedy) for infiltration use, a non-opioid analgesic making use of the impressive SABER® platform technology, is Fda-accredited and has been solely accredited to Innocoll Pharmaceuticals for progress and commercialization in the United States. For more information and facts about DURECT, be sure to visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-On the lookout Assertion
The statements in this press release about medical enhancement of larsucosterol (DUR-928) for opportunity treatment method of AH, the possible to acquire larsucosterol for NASH or other indications, the predicted industrial start of POSIMIR by Innocoll and possible foreseeable future payments we might receive from Innocoll are ahead-searching statements involving pitfalls and uncertainties that can cause true success to vary materially from those in this kind of forward-looking statements. Probable dangers and uncertainties incorporate, but are not minimal to, the dangers that the AHFIRM trial of larsucosterol in AH usually takes lengthier to perform than expected due to COVID-19 or other factors, the threat that ongoing and long term medical trials of larsucosterol do not affirm the effects from before scientific or pre-clinical trials, or do not reveal the protection or efficacy or the lifetime-preserving opportunity of larsucosterol in a statistically considerable manner, pitfalls that Innocoll could not commercialize POSIMIR correctly, if at all, and risks relevant to our ability to acquire cash to fund functions and expenses. Further more details concerning these and other challenges is provided in DURECT’s once-a-year report on Sort 10-K filed on March 8, 2022 with the Securities and Exchange Commission below the heading “Possibility Aspects.” The 10-K and other general public filings are available on our website www.durect.com under the “Buyers” tab.
Be aware: POSIMIR® is a trademark of Innocoll Prescription drugs, Ltd. in the U.S. and a trademark of DURECT Corporation outdoors of the U.S. SABER® is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective proprietors. Larsucosterol (DUR-928) is an investigational drug prospect beneath progress and has not been authorized for commercialization by the U.S. Food and Drug Administration or other well being authorities for any indication.
Resource DURECT Corporation